Evidence map›Paper›PMID 33422642›Full record

SynthesisContemporary clinical trials2021

Remdesivir for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials.

Ahmad Al-Abdouh, Anas Bizanti, Mahmoud Barbarawi, Ahmad Jabri, Ashish Kumar, Oluwaseun E Fashanu, Safi U Khan, Di Zhao, Annukka A R Antar, Erin D Michos

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Contemporary clinical trials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 9 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 9 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Remdesivir for the treatment of COVID-19.The Cochrane database of systematic reviews · 2023
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Remdesivir for the treatment of COVID-19.The Cochrane database of systematic reviews · 2021
    Pooled it
  10. Trial
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Potential use of renin-angiotensin-aldosterone system inhibitors to reduce COVID-19 severity.Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ahmad Al-AbdouhDepartment of Medicine, Saint Agnes Hospital, Baltimore, MD, USA. Electronic address: ahmad.al-abdouh@ascension.org.
Anas BizantiDepartment of Medicine, Saint Agnes Hospital, Baltimore, MD, USA.
Mahmoud BarbarawiDepartment of Cardiology, University of Connecticut, Storrs, CT, USA.
Ahmad JabriDepartment of Cardiology, MetroHealth Medical Center, Cleveland, OH, USA.
Ashish KumarDepartment of Critical Care Medicine, St Johns's Medical College Hospital, Bangalore, India.
Oluwaseun E FashanuDepartment of Medicine, Saint Agnes Hospital, Baltimore, MD, USA.
Safi U KhanDepartment of Medicine, West Virginia University, Morgantown, WV, USA.
Di ZhaoDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Annukka A R AntarDivision of Infectious Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Erin D MichosDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Funding

The HIV Latent Reservoir, Suboptimal Immune Response on Antiretroviral Therapy, and Exogenous Cytokine TherapiesK08AI143391 · NIAID · JOHNS HOPKINS UNIVERSITY · PI ANTAR, ANNUKKA AIDA ROSE · 2019 to 2023
$994k
NIAID NIH HHS K08 AI143391
6 · The paper itself

Abstract

backgroundThe nucleotide analogue prodrug remdesivir was among the first antiviral therapies to be tested in randomized controlled trials (RCTs) for COVID-19. We performed a meta-analysis to understand efficacy and safety.

methodsWe searched PubMed, EMBASE, Cochrane library, and ClinicalTrials.gov databases (from January 1, 2020 to November 5, 2020). We included RCTs comparing the efficacy and safety of remdesivir to control/placebo in COVID-19. Two independent investigators abstracted data, assessed the quality of evidence, and rated the certainty of evidence.

resultsA total of 4 RCTs with 7334 patients with COVID-19 were included. At a follow-up of 28-29 days from randomization, very low certainty evidence showed that use of remdesivir compared with control group (placebo and/or standard of care) was not associated with a significant decrease in time to clinical improvement (standardized mean difference -0.80 day; [CI, -2.12, 0.53]). However, moderate certainty of evidence showed that remdesivir was associated with higher rates of recovered patients (risk difference [RD] 0.07 [0.05, 0.08]) and discharged patients (RD 0.07 [0.03, 0.11]) and lower rates of developing serious adverse events (RD -0.05 [-0.10, -0.01]) compared with control. Moderate and very low certainty of evidence showed there was no significant difference in deaths at 28-29 days follow-up (RD -0.01 [-0.03, 0.01]) and developing any adverse events (RD 0.01 [-0.17, 0.19]) between both groups, respectively.

conclusionPatients given remdesivir are more likely to demonstrate recovery and were associated with higher rates of hospital discharge, but not with significant reduction in mean time to clinical improvement or mortality.

Indexed as

COVID-19COVID-19 Drug TreatmentAdenosine MonophosphateAlanineAntiviral AgentsHumansRandomized Controlled Trials as TopicSARS-CoV-2Treatment OutcomeAdenosine MonophosphateAlanineAntiviral AgentsremdesivirCOVID-19RemdesivirSARS-Cov-2

Identifiers

PMID33422642
PMCPMC7789823

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.